Injectable Fat Reduction Followup

Kevin C. Smith, MD, FAAD, presented results from a long-term followup of KYTHERA Biopharmaceutical’s ( ATX-101 injectable drug for submental fat reduction at the 2011 ASDS meeting in Washington, DC. Preliminary results show that at two year followup visits, greater than 90% of the 45 responders from the company’s phase 2A studies who are taking part in the long-term followup exhibited a sustained or improved response. Results were measured by physician evaluation using the Clinician-Reported Submental Fat Rating Scale. In addition, 80% of these subjects demonstrated sustained or improved satisfaction based on patient evaluation using the Subject Satisfaction Rating Scale.

More in News